Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 292


Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.

DeVita VT, Canellos GP.

Tumori. 2016 Apr 18;102(2):124-6. doi: 10.5301/tj.5000492. Epub 2016 Mar 22.


In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.


Advanced DLBCL: as systemic therapy improves, the need for RT diminishes.

Canellos GP.

Oncology (Williston Park). 2014 Dec;28(12):1085-6. No abstract available.


Treatment of Hodgkin lymphoma: a 50-year perspective.

Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.

J Clin Oncol. 2014 Jan 20;32(3):163-8. doi: 10.1200/JCO.2013.53.1194. No abstract available.


Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited.

Canellos GP.

Oncology (Williston Park). 2012 Dec;26(12):1199-200, 1202. No abstract available.


Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?

Canellos GP.

J Clin Oncol. 2012 Jun 20;30(18):2171-2. doi: 10.1200/JCO.2011.39.6416. Epub 2012 Apr 30. No abstract available.


Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD; Cancer Leukemia Group B.

Leuk Lymphoma. 2012 Nov;53(11):2143-50. doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28.


Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?

Cote GM, Canellos GP.

Curr Hematol Malig Rep. 2011 Sep;6(3):180-6. doi: 10.1007/s11899-011-0088-8. Review.


Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD; Cancer and Leukemia Group B.

Blood. 2011 May 19;117(20):5314-20. doi: 10.1182/blood-2010-10-314260. Epub 2011 Feb 25.


Hematology in 2010: New therapies and standard of care in oncology.

DeVita VT Jr, Canellos GP.

Nat Rev Clin Oncol. 2011 Feb;8(2):67-8. doi: 10.1038/nrclinonc.2010.221. Review. Erratum in: Nat Rev Clin Oncol. 2011 Jul;8(7):384.


End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS.

Ann Oncol. 2011 Apr;22(4):910-5. doi: 10.1093/annonc/mdq549. Epub 2010 Oct 15.


Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.

Canellos GP, Abramson JS, Fisher DC, LaCasce AS.

J Clin Oncol. 2010 Mar 20;28(9):1611-5. doi: 10.1200/JCO.2009.25.3260. Epub 2010 Feb 16.


Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option?

Canellos GP.

Oncologist. 2009 Dec;14(12):1167-8. doi: 10.1634/theoncologist.2009-0288. Epub 2009 Dec 11. No abstract available.


Long-term follow-up of survival in Hodgkin's lymphoma.

Canellos GP, Niedzwiecki D, Johnson JL.

N Engl J Med. 2009 Dec 10;361(24):2390-1. doi: 10.1056/NEJMc0906731. No abstract available.


What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?

Canellos GP, Mauch P.

J Clin Oncol. 2010 Jan 1;28(1):e8. doi: 10.1200/JCO.2009.26.3293. Epub 2009 Nov 23. No abstract available.


Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.

J Clin Oncol. 2009 Dec 20;27(36):6101-8. doi: 10.1200/JCO.2009.22.2554. Epub 2009 Nov 16.


Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH.

J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10.


What constitutes "improved prognosis"?

Canellos GP.

J Clin Oncol. 2008 Apr 20;26(12):1913-4. doi: 10.1200/JCO.2007.13.8172. No abstract available.


Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.

Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008.


Relapsed and refractory Hodgkin's lymphoma: new avenues?

Canellos GP.

Hematol Oncol Clin North Am. 2007 Oct;21(5):929-41. Review. Erratum in: Hematol Oncol Clin North Am. 2008 Aug;22(4):xi. Dosage error in article text.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk